Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb & Co. (NYSE: BMY ) announced topline results from its Phase 3 EXCALIBER-RRMM study on Thursday. The pharmaceutical company revealed its drug Zenbexus (iberdomide) significantly reduced the risk of disease progression or death in multiple myeloma patients. • Bristol-Myers Squibb stock is facing resi